Rubitecan sustained-release implant for treating solid tumor

A technology of sustained-release implants and rubitecan, which is applied in the directions of antineoplastic drugs, medical preparations with non-active ingredients, and medical preparations containing active ingredients, etc. and other problems, to achieve obvious therapeutic effect, reduce systemic toxicity, prolong the effect of local drug concentration

Inactive Publication Date: 2011-01-05
SHANDONG LANJIN PHARMA +1
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the sustained-release preparations made by the existing methods release faster and unstable, so that they cannot bring into play their clinical effects well.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

Embodiment 2

Embodiment 3

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A sustained release implant of rubitecan for treating solid tumors is characterized in that the sustained release implant includes effective dose of anticancer rubitecan, sustained release excipients and a certain quantity of sustained release moderator. Solid tumors include pancreatic cancer, lung cancer, liver cancer, breast cancer, cerebroma, ovarian cancer, prostatic carcinoma, esophageal carcinoma, lymphadenoma, osteosarcoma and colorectal cancer. Sustained release excipients mainly are copolymer of glycolic acid and hydroxyacetic acid and one or combination of polifeprosan, poly(L-lactide-co-ethyl phosphate), poly (L-lactide-co- phosphoric acid propyl); in the process of decompression, rubitecan can be slowly released to local tumor, thus maintaining effective drug concentration of local tumor as well as significantly reducing overall toxic reaction. Being placed at local tumor, the sustained release implant not only reduces overall toxic reaction of rubitecan, but also selectively improves drug concentration in local tumor, enhancing the therapeutic effects of non-operative therapy such as chemotherapy drugs and radiotherapy.

Description

A kind of rubitecan sustained-release implant for treating solid tumors (1) Technical field The invention relates to a sustained-release implant of rubitecan for treating solid tumors, belonging to the technical field of medicines. (2) Background technology Although the research on cancer has made great progress, its mortality rate is still in the forefront of various common causes of death. The latest data show that in 2006, 3 million people died of cancer in my country. The incidence of cancer is increasing year by year and tends to be younger. Statistics show that in less than 20 years, the incidence of cancer in my country has increased by 69%, and the mortality rate has increased by 29.4%. According to the latest statistics from the World Health Organization, the global cancer incidence rate will increase by 50% by 2020, and the number of patients will increase to 15 million. It is estimated that 4 million people will die of cancer every year in my country in 2020. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4745A61K9/00A61K47/34A61P35/00
Inventor 孔庆忠俞建江
Owner SHANDONG LANJIN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products